More on KNBWY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $16.28 |
|
|||
| Open | $16.49 | ||||
| 52 Wk High | $18.64 | ||||
| 52 Wk Low | $12.59 | ||||
| Day High | $16.65 | ||||
| Day Low | $16.29 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 83,160 | ||||
- KIRIN HYOKETSU Expands into U.S. RTD Market with Local Production
- Cowellnex and Metagen Launch Joint Research Utilizing Independently Acquired High‑Precision Gut Microbiota Data
- Kirin and Immunosens Launch Joint Development of a Self-Testing Service That Uses Urinary IgA to Visualize a Person’s Immune Status
- Kirin Holdings Co Ltd (2503:JP) (KNBWY) PT Raised to JPY2,500 at JPMorgan
- Kyowa Kirin names Abdul Mullick as CEO effective March 2026
- Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
- Citi Reiterates Buy Rating on Kirin Holdings Co Ltd (2503:JP) (KNBWY)
- Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
- FDA approves KOMZIFTI for relapsed NPM1-mutated acute myeloid leukemia
- Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukem
Entities mentioned with KNBWY
- FDA | View Related Stories »
- Genzyme/Sanofi-Aventis | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- Dividend | View Related Stories »
- AdCom | View Related Stories »
- Show More...
